TuHURA Biosciences, Inc./NV

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

HURA$1.51-9.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Research and development expenses	$4,968,596	$2,946,768	$14,477,204	$9,358,845
General and administrative expenses	1,761,007	783,459	9,145,378	2,595,860
Operating Loss	(6,729,603)	(3,730,227)	(23,622,582)	(11,954,705)
Other (Expense) Income:
Grant income	138,299	-	713,508	-
Interest expense	(16,532)	(2,002,886)	(16,532)	(3,615,466)
Interest income	6,060	132,767	135,624	197,449
Other expense	(185,019)	-	(185,019)	-
Change in fair value of Kineta merger holdback shares	(315,660)	-	(315,660)	-
Change in fair value of derivative liability	-	21,229	-	(313,772)
Total Other (Expense) Income	(372,852)	(1,848,890)	331,921	(3,731,789)
Net Loss	$(7,102,455)	$(5,579,117)	$(23,290,661)	$(15,686,494)
Series A Preferred cash dividend	(2,089)	-	(6,267)	-
Deemed dividend on warrant modifications	-	(965,177)	-	(965,177)
Net Loss attributable to common stockholders	$(7,104,544)	$(6,544,294)	$(23,296,928)	$(16,651,671)
Net Loss per share, basic and diluted	$(0.14)	$(0.54)	$(0.50)	$(1.37)
Weighted-average shares outstanding, basic and diluted	50,666,430	12,178,522	46,235,423	12,176,127

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.